Sight Sciences, Inc. (NASDAQ: SGHT) is a Healthcare company (Medical - Devices) with a market capitalization of $583M. The Maz Rating grades it against the other companies in its sector.
Sight Sciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $10.49, Sight Sciences, Inc. trades at 6.6x sales and 11.7x book value. Over the last twelve months it generated about $89M of revenue and a net loss of $29M. It runs a gross margin of 87.7%, an operating margin of -29.5% and a net margin of -32.1%. It shows return on equity of -51.7%, return on invested capital of -28.6% and a free cash flow yield of -2.9%. On the balance sheet: a debt-to-equity ratio of 0.86 and a current ratio of 5.04. Over the past 52 weeks the share price ranged from $3.38 to $11.60, with a beta of 2.40.
Sight Sciences, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 4 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients. Another notable offering is the TearCare System, a wearable eyelid technology employed by ophthalmologists and optometrists for managing dry eye disease (DED). The company makes its products available across the United States, reaching hospitals, medical centers, and eye care professionals through its direct sales force and distribution partners. Founded in 2010, Sight Sciences' corporate operations are based in Menlo Park, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Sight Sciences, Inc. (SGHT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 8.45% / 30% · (Cash+Inv) / Mkt Cap (36m) 15.9% / 30% · Interest income / Revenue 2.78% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 8.45% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 15.9% / 33% · Receivables / Mkt Cap (36m) 2.76% / 49% · Interest income / Revenue 2.78% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 8.45% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 15.9% / 33.33% · Receivables / Mkt Cap (24m) 2.76% / 33.33% · Interest income / Revenue 2.78% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 37.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 76.8% / 33.33% · Receivables / Avg Assets (4Q) 10.4% / 33.33% · Interest income / Revenue 2.78% / 5% | Fail |
| FTSE | Debt / Total Assets 39.1% / 33.33% · (Cash+ST Inv) / Total Assets 73.8% / 33.33% · (Cash+Recv) / Total Assets 86.5% / 33.33% · Interest income / Revenue 2.78% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Sight Sciences, Inc. (SGHT) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Sight Sciences, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.78% of each dividend: Sight Sciences, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.